Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2542
Dr. Hammers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2009- Johns Hopkins University/Bayview Medical CenterResidency, Internal Medicine, 2002 - 2005
Certifications & Licensure
TX State Medical License 2016 - 2026
MD State Medical License 2009 - 2022
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Start of enrollment: 2015 Mar 28
- SBRT (Stereotactic Body Radiation Therapy) in Combination With Nivolumab/Ipilimumab in Renal Cell Carcinoma (RCC) / Kidney Cancer Patients Start of enrollment: 2017 Mar 01
Publications & Presentations
PubMed
- 1 citationsPresence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.Miya B Hugaboom, Lena V Wirth, Kelly Street, Neil Ruthen, Opeyemi A Jegede
Cancer Discovery. 2025-05-02 - Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.Joseph Vento, Tian Zhang, Payal Kapur, Hans Hammers, James Brugarolas
Cancers. 2025-04-30 - A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-04-01
Press Mentions
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease ControlNovember 11th, 2024- National Cancer Institute Renews $11.5 Million Program of Excellence Award in Kidney CancerSeptember 19th, 2022
UT Southwestern Develops Test to Predict Immunotherapy Response in Kidney CancerJune 4th, 2019- Join now to see all
Professional Memberships
- Member
- Member
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
